Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region

Shedko, Elizaveta Dmitrievna; Khayrullina, Guzel; Головешкина, Е. Н.; Акимкин, В. Г.

doi:10.1007/s10096-021-04170-0

Cited by 9 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first report on such a phenomenon in the Russian Federation was published in 2017. A study devoted to the screening of M. genitalium resistance in four cities of the Russian Federation identified seven cases with combined resistance out of 659 cases in total (1.1%); however, more recent results reported in 2021 indicate that the prevalence of such isolates has increased up to 6.3% (17/268 cases) [ 36 , 37 ]. One of the plausible causes for the increase in the number of samples with such a genotype is selective pressure from macrolide and fluoroquinolone therapy due to the extensive use of these agents in both in-patient facilities and ambulatory treatment in recent years, especially in conjunction with anti-COVID-19 therapy [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

“…The empirical prescription of these agents without an opportunity for timely STD diagnosis and a lack of therapy efficacy checks via confirmatory tests at the same time could promote the clonal expansion of such strains. A reasonable switch to fluoroquinolone therapy in the case of the poor efficacy of macrolides provided ground for the development of the secondary resistance to the new family of antibiotics and contributed to the stabilization and circulation of such isolates in the population [ 37 ]. Considering the statistically significant increase in the fraction of strains with such genotypes, the use of alternative therapeutic regimens or the introduction of new antimicrobial agents is necessary to overcome this spreading resistance.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic Determinants of Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium and Their Prevalence in Moscow, Russia

et al. 2023

View full text Add to dashboard Cite

Macrolide (MLR) and fluoroquinolone (FQR) resistance in Mycoplasma genitalium (MG) has recently become a major problem worldwide. The available data on the prevalence of MLR and FQR in MG in Russia are limited. In this study, we aimed to evaluate the prevalence and pattern of mutations in 213 MG-positive urogenital swabs from patients in Moscow between March 2021 and March 2022. MLR- and FQR-associated mutations were searched in 23S rRNA as well as in the parC and gyrA genes using Sanger sequencing. The prevalence of MLR was 55/213 (26%), with A2059G and A2058G substitutions being the two most common variants (36/55, 65%, and 19/55, 35%, respectively). FQR detection showed 17% (37/213); two major variants were D84N (20/37, 54%) and S80I (12/37, 32.4%) and three minor variants were S80N (3/37, 8.1%), D84G (1/37, 2.7%), and D84Y (1/37, 2.7%). Fifteen of the fifty-five MLR cases (27%) simultaneously harbored FQR. This study revealed the high frequency of MLR and FQR. We conclude that the improvement of patient examination algorithms and therapeutic approaches should be combined with the routine monitoring of antibiotic resistance based on the sensitivity profiles presented. Such a complex approach will be essential for restraining the development of treatment resistance in MG.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Genetic Determinants of Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium and Their Prevalence in Moscow, Russia

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In 2006–2008, MRAMs were lacking in a minor study in Moscow and in 2013–2015, an MRAM and QRAM prevalence of 4.6% (St. Petersburg: 6.8%) and 6.2% (St. Petersburg: 3.9%), respectively, were identified in four Russian cities 4. Finally, in 2019, an MRAM and QRAM prevalence of 21.7% and 20.8%, respectively, were described in Moscow 5. Accordingly, MRAM-guided MG treatment needs to be implemented in Russia.…”

Section: Discussionmentioning

confidence: 99%

Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia

et al. 2022

View full text Add to dashboard Cite

ObjectivesAntimicrobial resistance in Mycoplasma genitalium (MG) is a poorly surveyed and controlled global health concern. We evaluated the first commercial dual resistance assay, AmpliSens M. genitalium-ML/FQ-Resist-FL assay, for detection of potential macrolide and quinolone resistance-associated mutations (MRAMs and QRAMs, respectively) and estimated the prevalence of these mutations in MG in St. Petersburg, Russia.MethodsUrogenital samples positive (n=145 from 2007 to 2020) and negative (n=56 from 2021) for MG in routine diagnostics were retrospectively analysed using the AmpliSens M. genitalium-ML/FQ-Resist-FL assay (Central Research Institute of Epidemiology, Moscow, Russia) and Sanger sequencing for validation.ResultsThe AmpliSens M. genitalium-ML/FQ-Resist-FL assay detected potential MRAMs and QRAMs with sensitivities of 100% (CI95% 83.9 to 100) and 92.3% (CI95% 66.7 to 99.6) and specificities of 99.2% (CI95% 95.6 to 100) and 100% (CI95% 97.2 to 100), respectively, in clinical specimens with ≥1000 MG geq/mL. In total, MRAMs were detected in 13.8% (CI95% 9.1 to 20.3) of samples, with 23S rRNA A2058G being the most prevalent mutation (45.0% (CI95% 25.8 to 65.8)). QRAMs were found in 9.0% (CI95% 5.3 to 14.7) of samples, with S83I the most frequent mutation (53.8% (CI95% 29.1 to 76.8)). Dual resistance was observed in 5.5% (CI95% 2.8 to 10.5) of samples. Potential MRAM and dual resistance rates significantly increased over time: from 0% in 2007–2008 to 25% (ptrend=0.0009) and 10% (ptrend=0.0447), respectively, in 2018–2020. QRAM rate appeared to increase (from 0% to 13%), but significance was not reached (ptrend=0.0605).ConclusionsThe rapid increase in MG antimicrobial resistance in St. Petersburg, especially prominent for MRAMs, necessitates implementation of macrolide resistance-guided therapy in Russia. The first commercial dual resistance assay, AmpliSens M. genitalium-ML/FQ-Resist-FL assay, was sensitive and specific for detection of potential MRAMs and QRAMs and could be valuable in macrolide resistance-guided therapies and possibly for surveillance of QRAMs. International surveillance of antimicrobial resistance-associated mutations in MG, further research into clinical relevance of several parC mutations and novel treatments are essential.

show abstract

“…Работа по из учению частоты распространения макролидоустой чивых штаммов в 5 городах России и Эстонии указы вает на относительно низкий уровень резистентности у M. genitalium -не более 5% [33]. По данным опубли кованных российских исследований, частота встречае мости мутаций, ассоциированных с устойчивостью к ма кролидам у M. genitalium, в Москве, Смоленске и Туле не превышает 6% [34][35][36]. Детекция мутаций Выявление специфических мутаций осуществляли с использованием модифицированного метода ПЦРРВ с эффектом гашения флюоресценции зонда праймером, описанным ранее [37].…”

Section: Monitoring Of Macrolide Resistanceassociated Mutations In My...unclassified

Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Edelstein

Руднева

Romanov

et al. 2022

CMAC

View full text Add to dashboard Cite

Objective. To determine spectrum and prevalence of genetic determinants of resistance to macrolides in Mycoplasma genitalium in a Russian patient population. Materials and Methods. A total of 873 M. genitalium-positive samples from five geographical regions of Russia were investigated over the period of 2009–2019 using the previously developed protocol of real-time polymerase chain reaction (allows detecting any nucleotide substitutions in the 23S rRNA gene of M. genitalium at positions 2058, 2059, and 2611). The results were confirmed using Sanger sequencing. Results. The most frequent mutations associated with resistance to macrolides in M. genitalium were the following: A2058G (60.5%) and A2059G (30.2%). The relatively rare mutations were A2058T (7%) and C2611T (2.3%). In the studied period, there was no trend to increase in frequency of mutations associated with resistance to macrolides. The study results are presented as an open project on the AMRcloud platform (https://amrcloud.net/ru/project/demares/). Conclusions. Our data emphasize a need to introduce regular screening of M. genitalium-positive samples for the presence of macrolide resistance-associated mutations into clinical practice.

show abstract

Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region

Cited by 9 publications

References 26 publications

Genetic Determinants of Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium and Their Prevalence in Moscow, Russia

Genetic Determinants of Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium and Their Prevalence in Moscow, Russia

Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia

Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Contact Info

Product

Resources

About